Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica

Executive Summary

AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.

You may also be interested in...



AstraZeneca’s Calquence Catches Up With Imbruvica’s CLL Claim

AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.

AZ’s Calquence Hits Endpoint In Second CLL Phase III Study

The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.

AZ, Pfizer, Lilly Novel Anticancers Head For India Debut

AstraZeneca’s Calquence, Pfizer’s Lorbrena and Lilly’s Verzenio, which all address unmet medical needs, have been endorsed by an expert panel in India, paving the way for their potential introduction on the market. But all eyes will be on pricing to ensure access in this largely self-pay market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel